Can-Fite BioPharma (NYSE:CANF) Earns Buy Rating from D. Boral Capital
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. Several other equities analysts have also weighed in on CANF. StockNews.com initiated coverage on shares of Can-Fite […]
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. Several other equities analysts have also weighed in on CANF. StockNews.com initiated coverage on shares of Can-Fite […]
